glp-1 obesity drug news october 21 2025 GLP-1s and Coverage: Differing Perspectives for Employers and Health Plans In U.S., GLP-1 Usage Reaches

Age, comorbidities, risk of side effects, cost, and your personal risk tolerance all matter

Anti-inflammatory activities of mogrosides from Momordica grosvenori in murine macrophages and a murine ear edema model

Since 2020, 8 of the 20 published clinical trials have focused on neurodevelopmental and neuropsychiatric/cognitive disorders, exhibiting a significant rise in clinical trials exploring sulforaphanes efficacy in the CNS compared to the previous two decades where only two of 57 trials focused on ASD alone with no published trials examining other CNS disorders (Supplementary Table 1)

Our next goal is to conduct prospective research that follows individuals initiating GLP-1 therapy over time, Abegaz said

Your experience is important to us

(1979) Effect of thiamine deficiency on brain serotonin turnover